FI
AVDL

Fosun International’s Avadel Pharmaceuticals AVDL Stock Holding History

Fosun International’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,997
Closed -$18K – 303
2019
Q1 		$18K Sell
11,997
-325,046
-96% -$735K ﹤0.01% 307
2018
Q4 		$826K Buy
+337,043
New +$1.15M 0.05% 160

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Fosun International's AVDL Position: Q2 2019 in Review

Fosun International sold out of Avadel Pharmaceuticals (AVDL) in Q2 2019, closing a stake of 11,997 shares — an estimated $18K sold.

Fosun International first reported a position in AVDL in Q4 2018 and held it in 2 quarters. The position peaked at $826K in Q4 2018. 45 funds tracked by Wall St. Rank hold AVDL as of Q2 2019.

  • Fosun International reported no remaining Avadel Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Fosun International sold 11,997 Avadel Pharmaceuticals shares in Q2 2019, an estimated $18K.
  • Fosun International first reported a position in Avadel Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Fosun International's Avadel Pharmaceuticals position peaked at $826K in Q4 2018.
  • 45 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2019.

Based on Fosun International's 13F filing for Q2 2019, filed 12 Aug 2019.